Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ChiCTR2600128833) titled 'A real world study of CDK4/6 inhibitor in the treatment of advanced breast cancer' on July 27.
Study Type: Observational study
Study Design:
Cohort study
Primary Sponsor: Zhejiang Cancer Hospital
Condition:
Advanced or metastatic breast cancer
Intervention:
Palbociclib group:None
Abemaciclib group:None
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2023-12-01
Target Sample Size: Palbociclib group:100;Abemaciclib group:100;Dalpiciclib group:100;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=216113
Disclaimer: Curated by HT...